Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MetaStat Inc MTST

Healthcare Technology Biotechnology Scientific & Technical Instruments
MetaStat, Inc. is a precision medicine company. The Company's therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. The Company's product development programs are focused on developing drug candidates and companion diagnostic tests that target the MENA pathway. Its pipelines include MENA Diagnostic... see more

Recent & Breaking News (GREY:MTST)

MetaStat, Inc. to Present at the 26th Annual ROTH Conference

eTeligis February 26, 2014

MetaStat, Inc. Launches Scientific Advisory Board for Therapeutics

Accesswire February 10, 2014

MetaStat, Inc. to Present at the 2014 BIO CEO & Investor Conference in New York City on February 11, 2014

Accesswire February 5, 2014

MetaStat, Inc. to Present at Biotech Showcase(TM) 2014 in San Francisco

Marketwired January 8, 2014

MetaStat, Inc. Announces Issuance of U.S. Patent for Its MenaCalc(TM) Platform

Marketwired December 23, 2013

MetaStat Announces Poster Presentation at the 2013 San Antonio Breast Cancer Symposium

Marketwired December 17, 2013

MetaStat Announces Exclusive Worldwide License Agreements for the Alternative Splicing Program in the Epithelial to Mesenchymal Transition (EMT) in Epithelial Cancers

Marketwired December 12, 2013

MetaStat, Inc. Announces Notice of Allowance for a U.S. Patent Supporting Its MenaCalc(TM) Platform

Marketwired November 11, 2013

MetaStat, Inc. Announces Notice of Allowance for a U.S. Patent Supporting Its MetaSite Breast(TM) Test

Marketwired November 6, 2013

Exclusive Video Interviews With CEOs Now on Equities.com: AHRO, AMBS, MTST, ONCS, TRGM

Globe Newswire October 9, 2013

MetaStat Announces Commencement of Its Comprehensive Drug Development Program with Significant New Hires and Research Facility Opening

Press Releases September 10, 2013

MetaStat CEO Dr. Oscar Bronsther Interviewed on The Wall Street Analyst

Accesswire July 9, 2013

Crystal Research Associates, LLC Issues Quarterly Update on MetaStat, Inc.

PR Newswire April 23, 2013

MetaStat Appoints David Epstein, Ph.D. as Advisor to Lead Drug Discovery

PR Newswire April 15, 2013

MetaStat announces DTC Eligibility

PR Newswire February 26, 2013

MetaStat to Present at Noble Financial Capital Markets' Ninth Annual Equity Conference on January 22, 2013

PR Newswire January 18, 2013

Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on MetaStat, Inc.

PR Newswire January 7, 2013

MetaStat, Inc. Announces Completion of 500 Patient Breast Cancer Trial

PR Newswire January 7, 2013

MetaStat Announces Presentations at the Biotech Showcase conference in San Francisco on Monday, January 7, 2013

PR Newswire January 3, 2013